AVEO Reports 2011 Financial Results and Highlights Fourth Quarter Progress

CAMBRIDGE, Mass.--(BUSINESS WIRE)--AVEO Pharmaceuticals, Inc. (Nasdaq: AVEO) today reported consolidated 2011 financial results and reviewed key progress achieved with its tivozanib and ficlatuzumab development programs in the fourth quarter of 2011. “The recent success of our Phase 3 registration trial of tivozanib in RCC, TIVO-1, marks an important milestone for AVEO as we prepare for our first NDA submission later this year,” said Tuan Ha-Ngoc, president and chief executive officer of AVEO. “

Feed Date: 
February 14, 2012